However, for the chemotherapy-free combined therapy strategy, whether the neoantigen vaccine can exert its strong anti-tumor response to enhance the therapeutic efficacy of antiangiogenic therapy and immunotherapy (such as Bev and anti-PD-1 antibody), as well as the potential mechanisms remain to be classified. This evidence concerns the gene PDCD1 and neoplasm.